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The cancer stem-cell (CSC) hypothesis suggests that there is a small sub-
set of cancer cells that are responsible for tumor initiation and growth, 
possessing properties such as indefinite self-renewal, slow replication, 
intrinsic resistance to chemotherapy and radiotherapy, and an ability to 
give rise to differentiated progeny. Through the use of xenotransplanta-
tion assays, putative CSCs have been identified in many cancers, often 
identified by markers usually expressed in normal stem cells. This is 
also the case in lung cancer, and the accumulated data on side popula-
tion cells, CD133, CD166, CD44 and ALDH1 are beginning to clarify 
the true phenotype of the lung cancer stem cell. Furthermore, it is now 
clear that many of the pathways of normal stem cells, which guide cel-
lular proliferation, differentiation, and apoptosis are also prominent in 
CSCs; the Hedgehog (Hh), Notch, and Wnt signaling pathways being 
notable examples. The CSC hypothesis suggests that there is a small 
reservoir of cells within the tumor, which are resistant to many standard 
therapies, and can give rise to new tumors in the form of metastases 
or relapses after apparent tumor regression. Therapeutic interventions 
that target CSC pathways are still in their infancy and clinical data of 
their efficacy remain limited. However Smoothened inhibitors, gamma-
secretase inhibitors, anti-DLL4 antagonists, Wnt antagonists, and CBP/ 
β-catenin inhibitors have all shown promising anticancer effects in early 
studies. The evidence to support the emerging picture of a lung cancer 
CSC phenotype and the development of novel therapeutic strategies to 
target CSCs are described in this review.
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The cancer stem-cell (CSC) hypothesis is a concept that has received a great deal of recent attention in recent years. 
Normal stem cells are characterized by a number of peculiar 
properties; multipotency, that is, the ability to differentiate 
into different cell types; self-renewal; and the ability to pro-
liferate. These properties clearly have important parallels in 
oncogenesis and malignancy. Indeed, the concept that tumors 
may be derived from a rare population of embryo-like cells 
was discussed by Virchow1 as early as the mid-nineteenth cen-
tury. Other physicians of the time postulated that cancers may 
arise from dormant embryonic remnants in the body, which 
become activated to form tumors.2,3 However, it is only in 
recent years that putative CSCs have been identified. CSCs 
can be defined as a rare population of stem-like cancer cells 
that define the clinical phenotype of tumors, with important 
roles in initiation, progression, and maintenance of tumors. 
An important concept in this model is that tumors are heter-
ogenous, composed of neoplastic cells, vasculature, immune 
cells, and stromal elements. According to this model, tumors 
may be regarded as abnormal organs that contain a hierarchy 
of cells including self-renewing stem cells and highly prolif-
erative progenitor cells that in turn give rise to the differenti-
ated cells comprising the bulk of the tumor.
It is important to note that although the CSCs may share 
many characteristics with normal stem cells, it is not certain 
that all CSCs in all cancer subtypes are derived from normal 
stem cells. It is also possible that cancer stem cells may arise 
from committed progenitor cells, which acquire stem-like 
characteristics. There is now evidence in many cancer sub-
types that CSCs may arise from both normal stem cells4–9 and 
differentiated progenitor cells.10–13 Importantly, one study in 
breast cancer has shown that undifferentiated estrogen recep-
tor (ER) negative and poorly differentiated ER positive tumors 
arise from mammary stem cells whereas less-aggressive ER 
positive tumors arise from ER positive intermediate progeni-
tor cells.14 Therefore, it is possible that the origin of CSCs may 
vary considerably among different cancers, among subtypes 
of individual cancers, and even among different stages of the 
same malignancy. This issue of the likely origin of CSCs has 
been reviewed in detail elsewhere.15
The experimental demonstration of the capacity for 
self-renewal, and the production of differentiated progeny, 
demonstrated by xenotransplantation models of metastasis, 
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has succeeded in identifying putative CSCs in many cancer 
subtypes such as cancers of the brain, breast, lung, and of the 
hematopoietic system.16–21 Many of these putative stem cells 
also exhibit resistance to standard forms of treatment such 
as chemotherapy and radiotherapy.22–25 This property is also 
shared by normal stem cells, often mediated by the overex-
pression of adenosine triphosphate–binding cassette (ABC) 
transporters that efflux drugs out of the cell, and conserva-
tion in CSCs is one of the likely causes of chemoresistance.26 
Therefore, CSCs can be the source of all the malignant cells 
in a primary tumor, can compose the small subset of drug- 
resistant cells that are responsible for relapse after a che-
motherapy-induced remission, and can give rise to distant 
metastases ( Fig. 1). Given that metastatic and relapsed tumors 
are responsible for the majority of cancer deaths, it may be 
reasonable to suppose that therapies that specifically target 
CSCs may help to improve outcomes.
LUNG CANCER CSC PHENOTYPE
In recent years, there has been an increasing amount 
of evidence to support a CSC phenotype in human lung can-
cer.19–21 Many of these markers have also been found in other 
tumors and indeed in normal stem cells. One such phenotype 
is the so-called side population (SP) cells, which are capa-
ble of excluding Hoechst 33342 dye by ABC transporters. In 
addition, cells expressing the cell surface markers CD133 and 
CD166, cells with elevated nuclear β-catenin and elevated 
aldehyde dehydrogenase activity have also been shown to be 
indicative of a stem-cell–like population (Table 1).
Side Population
SP cells are now widely regarded to be stem cells 
in a number of malignancies, such as lung, breast, and 
glioblastomas as well as in normal hematopoietic cells.25,27–30 
They are characterized by the ability to efflux Hoechst 33342 
dye from within the cell, and this particular subpopulation of 
cells can be isolated using fluorescence-activating cell sort-
ing (FACS). SP cells have been shown to exhibit many of the 
required characteristics of stem cells such as self-renewal, 
production of differentiated progenitor cells, and the capacity 
to form tumors in non-obese diabetic/severe combined immu-
nodeficiency mice. SP cells have been shown to express ABC 
transporters such as ABCG2, MDR1, ABCA2 etc., which 
have important roles in chemoresistance by active efflux of the 
drug from within the cell.28 SP cells have been successfully 
identified in both non–small-cell and small-cell lung cancer 
cell lines.19,31 Ho et al.19 examined the SP fraction in six non–
small-cell lung cancer (NSCLC) cell lines and a small num-
ber of clinical samples. They found that the SP fraction was 
the tumorigenic population in a xenotransplantation model 
requiring far fewer cells to initiate a tumor than the non-SP 
fraction. Subsequent analysis of the SP-derived tumors also 
showed their differentiation into both SP and non-SP cells. 
This repopulation ability was also confirmed in vitro. ABC 
transporters such as ABCG2, ABCA2, and MDR1 were sig-
nificantly up-regulated in the SP fraction, and the SP fraction 
demonstrated increased resistance to a panel of seven different 
chemotherapy drugs. In addition, human telomerase reverse 
transcriptase expression was higher in the SP, suggesting that 
this fraction may represent a reservoir with unlimited prolif-
erative potential for generating cancer cells. Salcido et al.31 
similarly examined the SP fraction in a number of small-cell 
lung cancer (SCLC) cell lines. The cell lines examined con-
tained SP cells at a rate of less than 1% of the total population. 
Again SP cells were much more tumorigenic than non-SP 
cells with as few as 50 to 100 SP cells successfully forming 
tumors in immunodeficient mice, and again the xenograft 
FIGURE 1.  CSC hypothesis—poten-
tial implications. A, CSCs are thought 
to be the subset of cancer cells that 
are capable of forming new metas-
tases and are capable of forming the 
full range of differentiated cells that 
comprise the tumor. B, CSCs are often 
resistant to standard chemotherapy 
and radiotherapy. Treatments that fail 
to eradicate the CSC subpopulation 
are likely to lead to relapse of disease. 
C, Successful CSC-directed thera-
pies may improve clinical outcomes 
by reducing the portion of tumor 
cells most likely to persist through 
standard therapies and most likely 
to cause relapse or metastasis. CSC, 
cancer stem cell.
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tumors subsequently regenerated both SP and non-SP cells. In 
addition, the neuroendocrine markers CD56 and CD90, char-
acteristic of SCLC, were expressed significantly less in SP 
fraction cells than in the non-SP fraction, consistent with the 
primitive nature of SP cells. SP fraction cells had up-regulated 
genes that are involved in pathways modulating stemness, 
including MYC, FGF1, OCT4, KLF4, NOTCH2, WNT, and 
ABCG2. These data strongly suggest that the SP population is 
composed of highly undifferentiated cells with stem cell-like 
characteristics and resistance to standard chemotherapy.
CD133
The CD133 antigen, also sometimes referred to as 
Prominin 1 (PROM1), is a 120 kDa five transmembrane gly-
coprotein. Its function is currently not known but its expres-
sion on the cell surface has been demonstrated to be a specific 
marker for CSCs in a number of malignancies including cen-
tral nervous system tumors, colon, breast, prostate, and ovar-
ian cancers.16,17,32–35 There is now also considerable evidence 
to suggest that CD133 expression on a subpopulation of lung 
cancer cells also identifies CSCs.20,36–38 Eramo et al.20 demon-
strated that there is a rare population of CD133 positive cells 
in SCLC and in all subtypes of NSCLC. Lung cancer cells dis-
sociated from primary tumors and grown in serum-free media 
containing epidermal growth factor and fibroblast growth 
factor formed spheroid bodies, which became enriched for 
CD133 positive cells and could be maintained indefinitely. In 
contrast, CD133 negative cells did not acquire CD133 positiv-
ity and died within 2 to 3 weeks of culture. Upon the exposure 
of CD133 positive cells to serum-containing media, the lung 
cancer spheres adhered to the plastic and acquired the typi-
cal morphological appearance of differentiated cells. In the 
process of differentiation CD133 expression was lost, con-
firming its specificity for undifferentiated cells. CD133 posi-
tive cells were also found to express BCRP1/ABCG2 ABC 
transporter and were found to be relatively chemoresistant to 
cisplatin, etoposide, paclitaxel, and gemcitabine. Xenograft 
experiments also established that the CD133 positive popula-
tion was highly tumorigenic, with as few as 104 CD133+ cells 
consistently generating tumors in NOD/SCID mice, whereas 
10 times that amount of CD133− cells were not tumorigenic. 
Subsequent histological examination of xenograft tumors 
confirmed the generation of a differentiated cell population 
with a similar number of CD133+ cells as the parent tumor. 
These results were largely replicated in the work of Bertolini 
et al.37 They also found a rare subpopulation of lung cancer 
cells expressing CD133 with a much lower level of positiv-
ity in normal lung tissue. Similarly, they also confirmed the 
increased tumor-initiating capacity of CD133+cells in xeno-
graft models. CD133+ cells isolated from established xeno-
grafts, primary tumor specimens, and cell lines by FACS were 
found to be considerably more tumorigenic upon injection 
into NOD/SCID mice. Gene-expression analysis showed that 
genes associated with maintenance of stemness such as OCT4 
and NANOG, and adhesion and motility genes such as α-6 
integrin and CXCR4, were up-regulated in CD133+ cells. In 
addition, the expression of ABC transporter genes associated 
with the multidrug-resistance phenotype such as ABCC1 and 
ABCG2 were also found to increase in the CD133+ fraction. 
Chemoresistance to cisplatin of the CD133+ fraction was 
demonstrated in both in vitro and in vivo models. In vitro, 
exposure of lung cancer cell line A549 to cisplatin resulted in 
an eightfold increase in the number of CD133+ cells. In vivo, 
mice with six different lung cancer xenografts were treated 
with weekly cisplatin. Mice were killed at 7 days after the last 
treatment and at the time of tumor regrowth. FACS analysis of 
the resected tumors revealed marked enrichment of CD133+ 
cells shortly after chemotherapy but this reverted to origi-
nal levels at time of tumor regrowth. These findings suggest 
that CD133+ cells persist in exposure to chemotherapy and 
are subsequently able to re-establish a tumor that had previ-
ously responded to treatment. Levels of CD133 expression 
in primary tumors as determined by immunohistochemistry 
were compared with clinical outcomes in a small cohort of 
advanced-stage patients undergoing platinum-based chemo-
therapy. There was a trend toward decreased progression-free 
survival in those patients found to express CD133 in their pri-
mary tumors, which is consistent with the above data regarding 
the relative chemoresistance of CD133+ cells. Interestingly, 
Zhu et al.39 have reported that in a murine intestinal model, 
PROM1/CD133 marks an adult solid tissue stem cell that is 
susceptible to neoplastic transformation, supporting a model 
of a Prom1/CD133+ cancer stem cell. Using tamoxifen-
induced Cre to activate fluorescence in CD133+ cells the 
investigators showed that PROM1/CD133 positivity success-
fully identifies normal stem cells in the intestine, giving rise 
to all differentiated cell types of the intestinal epithelium. In 
addition, activation of endogenous Wnt signaling in mice con-
taining a Cre-dependent mutant allele of β-Catenin resulted 
in neoplastic transformation of PROM1/CD133+ cells in the 
intestine. These data suggest that CD133+ normal stem cells 
may be the cell of origin in certain cancers. Furthermore, in 
SCLC, it has been suggested that the neuroendocrine-regulat-
ing transcription factor, achaete-scute complex homologue 1 
(ASCL1) may be an important regulator of stem-cell mark-
ers such as CD133 and aldehyde dehydrogenase (ALDH). 
Jiang et al.38 showed that ASCL1 caused induction of both 
CD133 and ALDH1A1, and that using siRNA transfection 
TABLE 1.  Putative Cancer Stem Cell Markers in NSCLC and 
SCLC
Type of Cancer CSC Marker References 
NSCLC SP Ho et al.19
CD 133 Eramo et al.20
Bertolini et al.37
ALDH Jiang et al.21
Ucar et al.53
CD166 Zhang et al.65
CD 44 Leung et al.69
Nuclear β-catenin Giangreco et al.75
Levina et al.76
SCLC SP Salcido et al.31
CD 133 Eramo et al.20
NSCLC, non–small-cell lung cancer; SCLC, small-cell lung cancer; SP, side 
population; ALDH, aldehyde dehydrogenase.
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to repress ASCL1 caused reduced growth and inhibited soft 
agar clonogenicity in cultured SCLC. It was also shown that 
SCLC direct xenograft tumors that were enriched for CD133 
positivity had greatly increased tumorigenicity. In addition, 
the knockdown of ASCL1 in these xenografts using ASCL1 
shRNA caused a marked decrease in their tumor-initiating 
potential when compared with controls. However, there have 
been some conflicting data on the role of CD133 and CSCs. 
Meng et al.40 found that CD133 status in A549 and H446 cell 
lines was not significantly related to proliferative capacity, 
invasiveness, drug resistance, or tumorigenic ability in xeno-
graft models. Salnikov et al.41 also demonstrated that CD133 
expression in NSCLC was not prognostic. Therefore, although 
there are some conflicting data in this area, the weight of the 
available data strongly suggests an important role for CD133 
in correctly identifying lung CSCs.
Aldehyde Dehydrogenase
ALDH enzyme activity has also emerged as a promis-
ing marker of CSCs and indeed of normal stem cells. It has 
been known for some time that ALDH is highly expressed in 
normal hematopoietic stem cells,42,43 and in addition to being 
a putative stem-cell marker, ALDH activity also has a known 
role in drug resistance.44–47 ALDH activity has been used as a 
basis for an FACS method to sort viable hematopoietic stem 
cells from mixed cell populations for further study (Aldeflour 
assay, Stem Cell Technologies, Vancouver, BC, V5Z 1B3, 
Canada). This method has been subsequently applied in 
many malignancies and ALDH activity has identified poten-
tial CSCs in leukemia, breast cancer, brain cancer, head and 
neck squamous cell cancers, colon cancer, and also now lung 
cancers.48–53 Patel et al.54 demonstrated that ALDH1A1 and 
ALDH3A1 were overexpressed in both squamous carcinoma 
and adenocarcinoma of lung compared with normal pneu-
mocytes whereas there was low expression of ALDH seen in 
small-cell lung tumors. ALDH levels were seen to be higher 
in smokers than in nonsmokers and were seen to increase as 
premalignant lesions compared with normal cells suggest-
ing an important role in tumorigenesis. Furthermore, Jiang 
et al.21 demonstrated that lung cancer cells with relatively 
high ALDH1 activity displayed in vitro features of CSCs, 
including capacities for proliferation, self-renewal, and dif-
ferentiation, resistance to chemotherapy, and expressing the 
previously discussed CSC surface marker CD133. Six lung 
cancer cell lines were analyzed using the Aldefluor assay and 
FACS and were found to have a rare population of cells with 
high ALDH1 activity at a rate of 0.6% to 2.9% in NSCLC cell 
lines, whereas the two SCLC cell lines did not exhibit any 
ALDH activity. ALDH+ cells were found to proliferate faster 
and produce a mixed population of ALDH+ and ALDH− cells 
in culture, whereas ALDH− cells could only generate more 
ALDH− cells thus suggesting that it is the ALDH+ fraction 
that has the capacity for self-renewal and subsequent produc-
tion of a heterogenous tumor cell population. The authors also 
showed that the majority (64%) of ALDH1 positive cells also 
stained positively for CD133 and that they displayed increased 
resistance to cisplatin, gemcitabine, doxorubicin, daunorubi-
cin, vinorelbine, and docetaxel. In addition, ALDH+ H353 
and H125 cells were shown to be highly tumorigenic in xeno-
graft experiments. ALDH1 cells readily produced tumors 
in the NOD/SCID mice whereas those cells without ALDH 
activity could only do so in one instance. Importantly in this 
study, high levels of ALDH1 protein expression were shown 
to correlate with clinical outcomes, with high ALDH activity 
indicating poor patient prognosis and a more advanced stage 
of disease. Ucar et al.55 also examined ALDH activity as a 
potential stem cell marker using the H522 lung cancer cell 
line as a model. ALDH+ cells exhibited capacity for differ-
entiation and self-renewal, giving rise to both ALDH+ and 
ALDH− cells whereas ALDH− cells in culture produced only 
ALDH− cells. In contrast to the findings by Jiang et al., how-
ever, cells with high ALDH activity were seen to grow slower 
in vitro than ALDH− cells did. In addition in their xeno-
graft models, both ALDH+ and ALDH− cells were capable 
of forming tumors in NOD/SCID mice and the initial rate of 
tumor growth was actually faster in ALDH− cells. However, 
with the further transfer of tumor cells into secondary and ter-
tiary recipient animals, ALDH+ cells eventually showed faster 
growth, whereas the tumor-initiating capacity of ALDH− cells 
decreased with each successive engraftment, thus reinforc-
ing the hypothesis that ALDH+ is indicative of the lung CSC 
phenotype.
CD166
CD166, also known as activated leukocyte cell adhesion 
molecule, is a membrane glycoprotein that has been implicated 
as a potential marker of CSCs. It has a variety of functions 
in normal tissues, such as intravasation of leukocytes into the 
central nervous system,56 migration of monocytes across endo-
thelia,57 and T-cell activation.58 It has also been shown to be 
present on normal mesenchymal stem cells and hematopoietic 
progenitor cells.59–61 In addition, CD166 has been shown to 
be an indicator of poor prognosis in a variety of cancers62–65 
and has been demonstrated to identify a CSC phenotype using 
murine xenotransplantation models in colorectal cancer.66 
Recently, CD166 has also been identified as a marker for CSCs 
in NSCLC.67 In this study, Zhang et al. took cells from resected 
primary NSCLC tumors and injected them subcutaneously into 
NOD/SCID mice. Unsorted cells had a low rate of xenograft 
formation with an approximate rate of tumor-initiating cells 
(TICs) of 1 in 400,000. Having excluded hematopoietic and 
endothelial cells, the cells were sorted according to CD166, 
CD133, CD44, and EpCAM expression to assess whether any 
of these markers would enrich for the CSC population. It was 
found that CD166 positive cells were far more likely to form 
tumors than CD166 negative cells or any of the other mark-
ers investigated. In fact, it was observed that 100-fold fewer 
CD166 positive cells were needed for xenograft formation 
compared with unsorted cells. Examination of the xenograft 
tumors using hematoxylin–eosin staining and immunohisto-
chemistry showed that CD166 positive cells replicated the his-
tological morphology of the parent tumors. It was also found 
that only CD166 positive cells were capable of forming tumor 
spheres, an often-used in vitro assay, to assess self-renewal 
capacity. Furthermore, when CD166 positive tumor spheres 
were dissociated into single cells, as few as 1 to 5 single cells 
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consistently initiated xenografts. Interestingly, this study found 
very little difference in the xenograft-initiating capacity of 
the CD133 positive fraction of tumor cells in comparison to 
CD133 negative cells, which stands in contrast to other stud-
ies that have identified CD133 as a marker of CSCs.20,37 In 
addition, this study sought to obtain a molecular signature for 
lung TICs by performing genome-wide transcriptome analy-
sis on CD166+ and CD166- tumor cell populations. It was 
found that glycine decarboxylase (GLDC) and the oncogenic 
stem-cell factor LIN28B were particularly associated with 
TICs as opposed to non-TICs. Furthermore, the knockdown 
of GLDC and LIN28B in lung tumor spheres using shRNAs 
demonstrated that GLDC and LIN28B were necessary for cel-
lular proliferation and tumorigenicity as measured by soft agar 
colony formation. It was also found that GLDC expression in 
NSCLC patient samples formed a subset of the CD166+ popu-
lation and was prognostic, with high GLDC levels predicting 
shorter overall survival. This development of a molecular and 
metabolic profile of CSCs may ultimately deliver important 
new therapeutic targets.
CD44
CD44 is a cell membrane glycoprotein, which in normal 
cells has important roles in cell to cell adhesion, interactions 
with the extracellular matrix and cell migration. It has also 
been shown to be an important identifier of CSCs in a vari-
ety of cancers, most notably perhaps in breast cancer,17 but 
also in prostate, pancreatic, and head and neck cancers.68–70 
A recent study by Leung et al.71 suggests that CD44 may also 
have a role in identifying lung cancer CSCs. The investigators 
analyzed the effect of CD44 positivity in a range of NSCLC 
cell lines. It was found that CD44 positive cells had a higher 
rate of tumor spheroid formation in vitro, higher rates of 
resistance to cisplatin chemotherapy, and increased metastatic 
potential in a murine xenotransplantation model. The CD44 
positive cells also had a higher rate of expression of the stem-
cell markers OCT4 and NANOG in addition to epithelial-
mesenchymal–transition markers such as SNAI1, CDH2, and 
VIM. Furthermore, high rates of CD44 expression in clinical 
tumor samples as analyzed by immunohistochemistry were 
prognostic in adenocarcinomas although not in squamous cell 
carcinomas.
Wnt/β-Catenin
The Wnt/β-Catenin signaling pathway is known to play 
key roles in controlling cellular proliferation and cellular dif-
ferentiation in both embryogenesis and in regulating homeo-
stasis in normal adult tissues. Ordinarily, β-Catenin levels are 
maintained at a low level in the cytoplasm, but the activation 
of the Wnt/β-Catenin pathway causes the translocation and 
accumulation of β-Catenin in the nucleus, thereby promot-
ing the transcription of Wnt target genes. The Wnt/β-Catenin 
pathway has been demonstrated to play a crucial role in the 
maintenance and regulation of normal stem cells in a number 
of organ systems, for example intestinal mucosa,72 skin,73 and 
bone.74 In addition, Wnt/β-Catenin signaling has been shown 
to be of importance in CSCs in a number of malignancies, 
such as colon cancer,5 cutaneous squamous cell carcinoma,75 
and chronic myeloid leukemia.76 More recently, there have 
been some studies to suggest a role for abberent β-Catenin 
signaling in lung cancer also. Gianfreco et al.77 investigated 
β-Catenin signaling in various preinvasive lung squamous 
cell carcinomas, using immunohistochemistry to localize 
β-Catenin activity. Normal and metaplastic lung specimens 
exhibited membranous β-Catenin only, whereas severely dys-
plastic specimens and carcinoma in situ frequently exhibited 
abundant nuclear β-Catenin levels, thereby suggesting a role 
for Wnt/β-Catenin signaling in lung tumorigenesis. In addi-
tion, work by Levina et al.78 has suggested correlation between 
high nuclear β-Catenin levels and lung cancer CSCs. On the 
basis of previous observations of intrinsic chemoresistance of 
CSCs, the authors treated lung (H460), ovarian (OVCAR-3), 
and breast (MCF-7) cell lines with chemotherapy (cisplatin, 
etoposide, doxorubicin) to create drug-surviving cells (DSCs) 
which were then investigated for their potential as CSCs. 
Lung cancer DSCs thus created were shown to be enriched 
for CD133 positivity, had higher expression of the embryonic 
stem-cell markers TRA-1–81, SSEA-3, and OCT4 and had 
higher expression of nuclear β-Catenin when compared with 
parent cells, all indicative of a stem-cell like phenotype. DSCs 
were also shown to have intrinsic capacity for tumor-sphere 
formation, and a high metastagenic potential when injected 
into NOD/SCID mice compared with parent cells, further 
emphasizing their status as CSCs. This study also reinforces 
the hypothesis that CSCs form the pool of drug-resistant cells 
that cause relapse of the disease after chemotherapy.
KRAS
KRAS mutations are frequently encountered in human 
lung cancers. Previous models using oncogenic KRAS trans-
genic mice, have shown markedly high rates of lung cancer 
formation.79 More recently, it has been shown that certain sub-
types of lung epithelial cells become hyperplastic in response 
to oncogenic KRAS, with bronchoalveolar stem cells (BASCs) 
and type II alveolar cells identified as putative cells of origin 
in KRAS induced lung carcinomas.4,80 Work by Kim et al.4 has 
shown that KRAS mutation may be a key event in the forma-
tion of lung cancers arising from normal BASCs. The authors 
developed a “Lox-stop-lox” KRAS conditional mouse strain 
in which expression of oncogenic KRAS is spatially and tem-
porally controlled by a removable transcriptional termination 
(stop) element. Infection of the mice with recombinant ade-
noviral Cre (AdCre) results in deletion of that stop element, 
producing the Lox-KRAS allele that expresses oncogenic 
KRAS. The authors showed that AdCre-induced activation of 
the KRAS allele increases the abundance of BASCs that are 
found at the bronchioalveolar duct junction. In addition, coad-
ministration of naphthalene and AdCre infection showed sig-
nificantly higher rates of tumor formation in Lox-KRAS mice 
compared with normogenic controls. These data support the 
hypothesis that BASCs may be the cell of origin for many lung 
adenocarcinomas, and that KRAS may have an important role 
in the malignant transformation of these normal stem cells 
during tumorigenesis. Regala et al.81 refined this hypothesis by 
examining the effect of matrix metalloproteinase-10 (MMP-
10) on KRAS mediated lung cancer initiation. Using a similar 
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mouse model, Lox-KRAS transgenic mice were crossed with 
MMP-10 knockout mice to create a bitransgenic mouse 
model. They showed that urethane-initiated lung tumors were 
far fewer in MMP-10 deficient animals compared with con-
trols, suggesting that MMP-10 may be an important cofactor 
in KRAS mediated BASC transformation and tumorigenesis. 
Furthermore, recent work by Xu et al.80 suggests that type 
II alveolar cells may also be cells of origin in certain KRAS 
induced lung adenocarcinoma. In this study, a similar mouse 
model was used, where two knock-in Cre-ER alleles were 
used to inducibly express oncogenic KRAS-G12D in Clara 
cell antigen 10 positive epithelial cells and surfactant protein 
C positive type II alveolar cells in murine lung tissue. It was 
shown that KRAS induction caused lung hyperplasia with type 
II cells, Clara cells, and BASCs, all possible as cells of ori-
gin. However, it seemed that only type II alveolar cells pro-
gressed to adenocarcinoma in response to oncogenic KRAS. 
Therefore, the data in this area clearly show that KRAS muta-
tion causes formation of lung carcinomas but further studies 
are necessary to further elucidate the likely cell or cells of 
origin in these tumors.
ESC Signature
The properties of embryonic stem cells (ESCs) have 
obvious parallels with cancer cells, such as self-renewal, mul-
tilineage differentiation, and proliferative capacity. ESC lines 
were first identified in 1998 and many studies have examined 
their molecular profiles, and determined panels of genes that 
are consistently over- or underexpressed compared with dif-
ferentiated cells.82,83
NANOG, OCT4, Sox2, c-Myc, Polycomb, and their tar-
gets are all crucially important in the regulation of ESC path-
ways and known to be involved in several cancer subtypes. 
Ben-Porath et al.84 demonstrated that in various human can-
cers, increased expression in an ESC signature and decreased 
expression of the Polycomb target genes correlated with 
poorly differentiated tumors and worse prognosis. These find-
ings were seen in gliomas, breast cancer, and bladder cancer.
Hassan et al.85 applied the same methodology to 
NSCLC in both adenocarcinomas and squamous cell carci-
nomas. Increased expression of a ESC gene set and decreased 
expression of Polycomb gene set identified poorly differen-
tiated, poor-prognosis adenocarcinoma tumors. This correla-
tion was not seen in squamous cell cancers. In a similar study, 
Stevenson et al.86 also found that an ESC signature in NSCLC 
correlated with a poor prognosis and resistance to cisplatin. It 
is important to note however, that these studies did not seek 
to identify a marker of a subpopulation of cancer stem cells 
within tumors but instead looked at the expression of ESC-
associated genes in whole tumors and how this affects the 
clinical behavior of the cancer.
CSCS AS A POTENTIAL THERAPEUTIC TARGET
As previously discussed, the CSC hypothesis suggests 
that there is a small subset of cancer cells that are responsible 
for tumor initiation and growth, possessing properties such as 
indefinite self-renewal, slow replication, intrinsic resistance to 
chemotherapy and radiotherapy, and an ability to give rise to 
differentiated progeny. In this model, CSCs may comprise just 
a small proportion of a tumor, but give rise to variably differ-
entiated progenitor cells with limited proliferative potential, 
which comprise the bulk of the tumor.
If the CSC hypothesis is correct, this has some critical 
implications for cancer therapeutics. Traditionally, the effi-
cacy of treatments such as chemotherapy and radiotherapy 
has been measured by assessing the degree of shrinkage of the 
tumor in response to therapy, either radiologically, or by clini-
cal examination. However, it is clear that many patients are 
intrinsically resistant to conventional therapies, and even in 
patients in whom a complete response to therapy is observed, 
all too often there are subsequent relapses of disease. Indeed, 
even in patients who have undergone tumor resection and 
adjuvant therapies, large numbers of patients have subse-
quent recurrence of disease, often long after initial diagnosis. 
This suggests that to improve outcomes in these situations it 
may be necessary to specifically target the CSC population, 
which are theorized to comprise the small pool of cells that 
are resistant to therapy and can cause relapse and metasta-
sis, even after periods of apparent dormancy after seemingly 
effective treatment. A key aspect of CSCs that has been iden-
tified to date is their intrinsic resistance to chemotherapy and 
radiotherapy.22–25 In the case of chemotherapy resistance this is 
often a result of the presence on CSCs of drug-efflux mecha-
nisms such as ABC transporters.26 In other cases, increased 
DNA repair capacity or resistance to reactive oxygen species 
cause intrinsic resistance of CSCs to radiation.22,87 The elu-
cidation of a CSC phenotype has revealed a range of cellu-
lar pathways that are relatively specific to stem cells and are 
potential targets for drug therapy. Sonic Hedgehog, Notch, 
and Wnt signaling pathways all have important roles in regu-
lating control of self-renewal and developmental pathways in 
normal stem cells,88–90 and have been shown to have important 
roles in CSC also.91–95 These pathways have received recent 
attention as potential therapeutic targets that may successfully 
target CSCs ( Fig. 2).
Hedgehog
Hedgehog (Hh) signaling is an important cell-signaling 
pathway in ESCs.88,96 Hh ligands act through the cell surface 
protein Patched and henceforth through the G-protein coupled 
receptor SMO, thereby activating downstream transcription 
factors ( Fig. 2). The binding of Hh ligands to cell surface 
protein Patched causes cell membrane localization of SMO 
and the initiation of a signaling cascade leading to the acti-
vation of the glioma-associated (Gli) family of transcrip-
tion factors. There is evidence that the Hedgehog pathway is 
important in several cancer subtypes97,98 and specific evidence 
of the importance of Hh signaling in SCLC,99,100 including 
data that shows that blocking Hh signaling can have an anti-
tumor effect.101 This has led to the development of a number 
of new Hh antagonists that are under investigation, some of 
which are now in clinical trials.102 The archetypal Hh specific 
inhibitor is cyclopamine, a plant-derived SMO antagonist. 
Cyclopamine was first identified as a cause of severe congeni-
tal defects such as cyclopia in animals,103 and subsequently 
its mode of action as a SMO inhibitor was elucidated.104,105 
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More recently, novel small molecule SMO antagonists, GDC-
0449, IPI-926, and BMS-833923/XL139 have entered clini-
cal trials. Of these compounds, IPI-926 has some evidence 
for efficacy in SCLC in a primary xenograft model.106 Initial 
studies with GDC-0449 have shown promising results in basal 
cell carcinoma107 and medulloblastoma.108 GDC-0449 is now 
being evaluated in SCLC in the form of a phase II clinical 
trial (Eastern Cooperative Oncology Group 1508) in combina-
tion with cisplatin and etoposide. IPI-926 and BMS-833923/
XL139 are in phase I studies in SCLC in combination with 
standard chemotherapy. Clinical data from these studies are 
not yet available and are eagerly awaited.
Notch
The Notch signaling pathway is a cell to cell communica-
tion system, which is known to play a critical role in regulating 
cellular proliferation and differentiation during embryogenesis 
and in normal adult stem cells.109,110 Notch pathways are known 
to be abnormal in several cancer subtypes including NSCLC 
and SCLC.31,111–115 There are four mammalian Notch receptors 
(Notch 1–4), each comprising an extracellular domain, a trans-
membrane domain and an intracellular domain (NICD). Notch 
receptors bind to two distinct families of Notch ligands, Delta-
like (DLL1, DLL3, DLL4) and Jagged-like (JAG1, JAG2). 
Ligand-receptor binding causes the Notch receptor to undergo 
a conformational change, thereby exposing a previously hidden 
portion to enzymatic cleavage. NICD is cleaved by a disintegrin 
and metalloproteinase metalloproteinase/tumor necrosis factor-
α−converting enzyme, and thereafter by gamma-secretase, 
releasing NICD from the cell membrane. NICD then trans-
locates to the nucleus and binds to the transcription initiation 
complex and core-binding factor-1 (CBF-1) thus inducing tran-
scription of Notch target genes116 (Fig. 2). Gamma-secretase 
inhibitors which block the enzymatic cleavage and consequent 
activation of Notch, are potential therapeutic agents to target 
CSCs. Two such gamma-secretase inhibitors, RO4929097 and 
MK0752, are now in early clinical development with clini-
cal trials now underway in a number of cancers including in 
NSCLC.117–119 A further approach has been to target DLL4. 
DLL4 is a Notch ligand known to be involved in angiogene-
sis and anti-DLL4 therapies such as the monoclonal antibody 
OMP-21M18 have been developed. There is preclinical and 
clinical evidence that this approach decreases the incidence of 
CSCs in colon cancer,120 and OMP-21M18 is now also under 
investigation in lung cancer.
Wnt
As previously discussed, the Wnt signaling pathway is 
known to play key roles in controlling cellular proliferation 
and cellular differentiation in both embryogenesis121 and in 
regulating stem cells in normal adult tissues.72–74 Abnormal or 
deregulated Wnt signaling has also been observed in several 
FIGURE 2. A, Hh signaling pathway. Hh ligand binding to the transmembrane receptor PTCH causes membrane localization 
of SMO. SMO activation causes liberation and nuclear translocation of glioma-associated family of transcription factors, thereby 
inducing transcription of Hh target genes. B, NOTCH signaling pathway. DLL of JAG ligands on adjacent cells bind to the trans-
membrane receptor Notch. Ligand binding causes a conformational change in Notch thus causing enzymatic cleavage of the 
receptor by ADAM/TACE and gamma-secretase. This liberates the intracellular portion of NOTCH (NICD), which then translo-
cates to the nucleus. NICD complexes with core-binding factor-1 and initiates transcription of NOTCH target genes.  
C, Canonical Wnt signaling pathway. Wnt ligands bind to the transmembrane receptor Fz. Activation of Fz causes the inhibition 
of the action of GSK-3, APC, and Axin on b-catenin, thereby increasing cellular levels of b-catenin. b-catenin then translocates 
to the nucleus where it complexes with transcriptional c-factors such as TCF/LEF and CBP thereby causing the transcription of 
Wnt target genes. Hh, Hedgehog; a disintegrin and metalloproteinase/TACE, a disintegrin and metalloproteinase/tumor necrosis 
factor-α−converting enzyme; NICD, notch intracellular domain; Fz, Frizzled; GSK, glycogen synthase kinase; APC, anaphase 
promoting complex; TCF/LEF, T-cell factor/lymphoid enhancer factor; CBP, CREB-binding protein.
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cancer subtypes including lung cancer.6,75–78,122,123 Wnt proteins 
are a family of 19 glycoproteins that act as ligands for the 
Frizzled (Fz) transmembrane receptor. The binding of Wnt 
ligands to Fz receptors activates two distinct signal transduc-
tion pathways, known as the canonical and noncanonical Wnt 
pathways. The canonical pathway causes an accumulation of 
β-catenin in the nucleus and consequent transcription of Wnt 
target genes. (Fig. 2) A number of strategies to inhibit Wnt/β-
catenin signaling to target CSCs have been investigated. For 
example, monoclonal antibody antagonists to Wnt-1 and 
Wnt-2 have been developed with some early evidence of anti-
tumor efficacy in a number of cancers, including NSCLC.124–
127 Another technique has been the use of small molecules 
to antagonize the binding of β-catenin to the transcriptional 
cofactor cyclic AMP response element binding protein (CBP). 
One such molecule, ICG-001, has shown in vitro anticancer 
efficacy in a colon cancer model128 whereas another CBP/β-
catenin antagonist, PRI-724, has entered early clinical trials.129 
Furthermore, inhibitors of Disheveled (Dsh), a key protein in 
the Wnt signaling pathway, have also shown some preclinical 
antitumor activity.130
DISCUSSION
The CSC hypothesis now seems increasingly well estab-
lished in a wide range of malignancies. Through the use of 
xenotransplantation assays, putative CSCs have been identi-
fied in many cancers, often identified by markers that are held 
in common with normal adult or ESC. This is also now the case 
in lung cancer, and the accumulated data on SP cells, CD133, 
CD166, CD44, and ALDH1 are beginning to clarify the true 
phenotype of the lung cancer stem cell. Furthermore, the sig-
naling pathways that are characteristic of CSCs are becoming 
more clearly understood. It is now clear that many of the path-
ways of normal stem cells, which guide cellular proliferation, 
differentiation, and apoptosis are also prominent in CSCs, the 
Hedgehog (Hh), Notch, and Wnt signaling pathways being 
notable examples. This gives rise to many notable potential 
targets for new anticancer therapies and indeed the prospect 
of specific anti-CSC therapies. As previously stated, the CSC 
hypothesis has some critically important implications for how 
we view cancer chemotherapy and how we assess efficacy of 
treatments. The CSC hypothesis suggests that there is a small 
reservoir of cells within the tumor, which are resistant to many 
standard therapies, and can give rise to new tumors in the form 
of metastases or relapses after apparent tumor regression. It is 
possible therefore that the more important issue when assess-
ing an anti-CSC therapy may not be measuring how much of 
the tumor bulk it reduces but which type of cells it targets 
and whether it can successfully eradicate the CSC subpopu-
lation. Therapeutic interventions that target CSC pathways 
are still in their infancy and clinical data of their efficacy are 
extremely limited as yet. However SMO inhibitors, gamma-
secretase inhibitors, anti-DLL4 antagonists, Wnt antagonists, 
and CBP/β-catenin inhibitors have all shown some promising 
results in preclinical studies and in early clinical trials. Several 
examples of these drugs have now entered early-stage clini-
cal trials in lung cancer. It is also important to remember that 
many CSC pathways are replicated in normal adult stem cells. 
Therefore there may be unforeseen toxicities associated with 
anti-CSC therapies which may only become clear with more 
extensive clinical use of these drugs. Although it is important 
to maintain this note of caution, our better understanding of 
the nature of CSCs gives rise to some tantalizing prospects 
of new therapies which may help to eradicate tumors more 
effectively, reduce risk of relapse and metastasis, and improve 
clinical outcomes for patients with lung cancer.
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